Adherex Technologies (FENC) to Release Quarterly Earnings on Monday

Adherex Technologies (NASDAQ:FENC) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Adherex Technologies to post earnings of $0.01 per share and revenue of $14.7330 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 25, 2026 at 9:30 AM ET.

Adherex Technologies Stock Down 1.4%

NASDAQ:FENC opened at $8.49 on Monday. The stock has a market cap of $290.53 million, a P/E ratio of -36.91 and a beta of 0.75. The business’s 50-day moving average price is $7.92 and its two-hundred day moving average price is $8.26. Adherex Technologies has a twelve month low of $4.68 and a twelve month high of $9.92.

Wall Street Analysts Forecast Growth

FENC has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adherex Technologies in a research note on Thursday, January 22nd. Zacks Research raised shares of Adherex Technologies from a “strong sell” rating to a “hold” rating in a report on Friday, December 12th. Wall Street Zen upgraded shares of Adherex Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 14th. B. Riley Financial began coverage on Adherex Technologies in a research note on Thursday, February 12th. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Piper Sandler began coverage on Adherex Technologies in a research report on Friday, January 9th. They set an “overweight” rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $14.80.

Insider Buying and Selling at Adherex Technologies

In other news, Director Rosty Raykov sold 10,349 shares of Adherex Technologies stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $7.76, for a total value of $80,308.24. Following the transaction, the director owned 98,477 shares in the company, valued at approximately $764,181.52. The trade was a 9.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Southpoint Capital Advisors Lp sold 1,000,000 shares of the stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $7.50, for a total value of $7,500,000.00. Following the sale, the insider owned 2,744,741 shares of the company’s stock, valued at $20,585,557.50. This represents a 26.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,020,349 shares of company stock valued at $7,655,708 over the last three months. 10.98% of the stock is currently owned by insiders.

Institutional Trading of Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. Jane Street Group LLC bought a new position in Adherex Technologies Inc. (NASDAQ:FENC) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned 0.05% of Adherex Technologies as of its most recent SEC filing. 55.51% of the stock is currently owned by institutional investors.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.